Astria therapeutics inc ATXS.US 總覽分析
ATXS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
ATXS 近期報酬表現
3.88%
Astria therapeutics inc
3.56%
同產業平均
1.47%
S&P500
與 ATXS 同產業的標的表現
- ACOG Alpha cognition inc價值 -趨勢 1 分波段 -籌碼 -股利 1 分查看更多
ATXS 公司資訊
Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.